Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) EBT Margin (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed EBT Margin for 16 consecutive years, with 13.5% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 1590.0% to 13.5% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 66.3% through Dec 2025, down 5391.0% year-over-year, with the annual reading at 66.3% for FY2025, 5391.0% down from the prior year.
  • EBT Margin for Q4 2025 was 13.5% at Harvard Bioscience, down from 5.51% in the prior quarter.
  • The five-year high for EBT Margin was 11.71% in Q2 2022, with the low at 233.28% in Q1 2025.
  • Average EBT Margin over 5 years is 17.88%, with a median of 4.71% recorded in 2023.
  • The sharpest move saw EBT Margin soared 2841bps in 2023, then crashed -21499bps in 2025.
  • Over 5 years, EBT Margin stood at 3.42% in 2021, then tumbled by -192bps to 3.14% in 2022, then fell by -25bps to 3.92% in 2023, then skyrocketed by 161bps to 2.4% in 2024, then tumbled by -662bps to 13.5% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 13.5%, 5.51%, and 11.02% for Q4 2025, Q3 2025, and Q2 2025 respectively.